This site is intended for healthcare professionals
General Practice Notebook
Medical search

Nordic Diltiazem study

FREE subscriptions for doctors and students... click here
You have 3 open access pages.

  • this is a randomised trial of the effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular mortality and morbidity in hypertension
  • randomised, blinded, controlled trial; 4.5 years mean follow-up
  • patients:
    • 10, 881 patients aged 50-69 years (extended to 74 years during the study) with a diastolic blood pressure >= 100 mmHg on 2 occasions; mean age of patients was 60 years old and 51% of patients were women
  • intervention:
    • allocated to treatments with diltiazem (n=5410) or diuretics or beta-blockers, or both (n=5471)
      • the treatment regimen for the diltiazem group was intensified if hypertension persisted with step-wise addition of ACE inhibitor, beta-blocker or an alpha blocker, and any other antihypertensive drug
      • in the non-diltiazem group treatment was started with a beta-blocker or diuretic. If necessary there was the stepped addition of the other drug, an ACE inhibitor or alpha-blocker, and any other antihypertensive drug (except a calcium antagonist)
  • outcome measures used were blood pressure and combined fatal and non-fatal stroke, fatal and non-fatal myocardial infarction (MI) and other CV death
  • results/conclusions:
    • diltiazem was as effective as diuretics, beta-blockers or both in the prevention of the combined end-point of stroke, myocardial infarction, and other cardiovascular death
    • in patients remaining in the study >= 24 months the reduction in systolic BP (but not diastolic BP) were smaller in the diltiazem group than in the diuretics and beta-blocker group (20/19 vs 23/19 mmHg, p<0.001)

Reference:

  • (1) Hansson L et al, for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet, 356, 359-65.

Links:

General Practice Notebook
General Practice Notebook
The information provided herein should not be used for diagnosis or treatment of any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Copyright 2016 Oxbridge Solutions LtdĀ®. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions LtdĀ® receives funding from advertising but maintains editorial independence. GPnotebook stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook.